Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study

Supportive Care in Cancer

Volumn 23, Issue 1, 2015, Pages 253-261

  Keefe, Dorothy M K ^a   Chan, Alexandre ^b   Kim, Hoon Kyo ^c   Hsieh, Ruey Kuen ^d   Yu, Shiying ^e   Wang, Yachuan ^f   Nicholls, Rebecca J ^g   Burke, Thomas A ^h  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c The Catholic University of Korea   (South Korea)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f Merck Sharp and Dohme Corp   (Taiwan)

^g OptumInsight Inc   (Australia)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer; Chemotherapy; Nausea; Observational; Vomiting

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINA; CLINICAL PRACTICE; CLINICAL STUDY; FEMALE; HIGHLY EMETOGENIC CHEMOTHERAPY; HUMAN; INCIDENCE; INDIA; INTEGRATIVE MEDICINE; MALE; MODERATELY EMETOGENIC CHEMOTHERAPY; OBSERVATIONAL STUDY; SINGAPORE; SOUTH KOREA; TAIWAN; AGED; CHEMICALLY INDUCED; COST OF ILLNESS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDY; QUESTIONNAIRE; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; AUSTRALIA; CHINA; COST OF ILLNESS; FEMALE; HUMANS; INCIDENCE; INDIA; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REPUBLIC OF KOREA; VOMITING;

EID: 84918773803     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2374-1     Document Type: Article

References (31)

1. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243. doi:10.1093/annonc/mdq194
2. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494. doi:10.1056/NEJMra0706547
3. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472–4478
4. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497–503
5. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117. doi:10.1007/s00520-010-1073-9
6. Perwitasari DA, Atthobari J, Mustofa M, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, Nortier JW, Guchelaar HJ, Kaptein AA (2012) Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer. Int J Gynecol Cancer 22(1):139–145. doi:10.1097/IGC.0b013e318234f9ee
7. Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P (2011) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 19(10):1549–1563. doi:10.1007/s00520-010-0982-y
8. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10(2):139–145
9. Yap KY, Low XH, Chui WK, Chan A (2012) Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting. J Clin Psychopharmacol 32(2):207–217. doi:10.1097/JCP.0b013e31824888a1
10. Bourdeanu L, Frankel P, Yu W, Hendrix G, Pal S, Badr L, Somlo G, Luu T (2012) Chemotherapy-induced nausea and vomiting in asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy. J Support Oncol 10(4):149–154. doi:10.1016/j.suponc.2011.10.007
11. Hassan BA, Yusoff ZB (2011) Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 12(1):185–191
12. Olver I, Molassiotis A, Aapro M, Herrstedt J, Grunberg S, Morrow G (2011) Antiemetic research: future directions. Support Care Cancer 19(Suppl 1):S49–S55. doi:10.1007/s00520-010-1036-1
13. Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16(2):201–208. doi:10.1007/s00520-007-0343-7
14. Molassiotis A, Farrell C, Bourne K, Brearley SG, Pilling M (2012) An exploratory study to clarify the cluster of symptoms predictive of chemotherapy-related nausea using random forest modeling. J Pain Symptom Manag 44(5):692–703. doi:10.1016/j.jpainsymman.2011.11.003
15. National Comprehensive Cancer Network (NCCN) (2013) Antiemesis guidelines. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed 24 February 2014
16. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198. doi:10.1200/JCO.2010.34.4614
17. Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992. doi:10.1093/annonc/mds021
18. Liau CT, Chu NM, Liu HE, Deuson R, Lien J, Chen JS (2005) Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians’ and nurses’' estimation vs. patients’ reported outcomes. Support Care Cancer 13(5):277–286. doi:10.1007/s00520-005-0788-5
19. Chan A, Shih V, Chew L (2008) Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. J Oncol Pharm Pract 14(1):23–29. doi:10.1177/1078155207084009
20. So WK, Chan DN, Chan HY, Krishnasamy M, Chan T, Ling WM, Lo JC, Aranda S (2013) Knowledge and practice among Hong Kong oncology nurses in the management of chemotherapy-induced nausea and vomiting. Eur J Oncol Nurs 17(3):370–374. doi:10.1016/j.ejon.2012.10.001
21. Chung SK, Ahn MJ, Yoo JY, Choi M, Hyang N, Woo SR, Kim SS, Kim SA, Oh EG (2011) Implementation of best practice for chemotherapy-induced nausea and vomiting in an acute care setting. Int J Evid Based Healthc 9(1):32–38. doi:10.1111/j.1744-1609.2010.00198.x
22. Hassan BA, Yusoff ZB (2010) Negative impact of chemotherapy on breast cancer patients QOL—utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev 11(6):1523–1527
23. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103–109
24. Uppsala Monitoring Center (2010) WHO Drug Dictionary version 3, 01 September 2010. http://www.umc-products.com/?&mn1=1105. Accessed 24 February 2014
25. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34(2):148–159
26. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11(8):522–527
27. American Society of Clinical Oncology (ASCO) The quality oncology practice initiative (QOPI). http://qopi.asco.org/. Accessed 24 February 2014
28. Hsieh R-K, Chan A, Kim H-K, Yu S, Kim J-G, Lee M-A, Dalén J, Jung H, Chung J-M, Burke TA, Keefe D (2014) The incidence of chemotherapy-induced nausea and vomiting within and across Asia Pacific countries following moderately and highly emetogenic chemotherapy. Support Care Cancer: under consideration
29. Yu S, Burke TA, Chan A, Kim H-K, Hsieh R-K, Hu X, Liang J-T, Banos A, Spiteri C, Keefe D (2014) Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a description of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer: under consideration
30. Chan A, Kim H-K, Hsieh R-K, Yu S, Lopes G, Su W-C, Banos A, Bhatia S, Burke TA, Keefe D (2014) Incidence and predictors of anticipatory CINV in Asia Pacific clinical practice—a longitudinal analysis Support Care Cancer: under consideration
31. Kim H-K, Hsieh R-K, Chan A, Yu S, Han B, Gao Y, Banos A, Ying S, Burke TA, Keefe D (2014) Impact of CINV in earlier cycles on chemotherapy regimen modification and CINV in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer: under consideration